These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 30306428)

  • 21. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
    Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?
    Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R
    Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
    Alfarsi L; Johnston S; Liu DX; Rakha E; Green AR
    Histopathology; 2018 Oct; 73(4):545-558. PubMed ID: 29603357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
    Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
    Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
    Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
    Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    Mudduwa L; Peiris H; Gunasekara S; Abeysiriwardhana D; Liyanage N; Rayala SK; Liyanage T
    BMC Cancer; 2018 May; 18(1):589. PubMed ID: 29793439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
    Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
    Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinesin 18A expression: clinical relevance to colorectal cancer progression.
    Nagahara M; Nishida N; Iwatsuki M; Ishimaru S; Mimori K; Tanaka F; Nakagawa T; Sato T; Sugihara K; Hoon DS; Mori M
    Int J Cancer; 2011 Dec; 129(11):2543-52. PubMed ID: 21213216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
    Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
    J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma.
    Liao W; Huang G; Liao Y; Yang J; Chen Q; Xiao S; Jin J; He S; Wang C
    Oncotarget; 2014 Nov; 5(21):10271-9. PubMed ID: 25431949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
    Richman J; Dowsett M
    Nat Rev Clin Oncol; 2019 May; 16(5):296-311. PubMed ID: 30563978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
    Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
    Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
    Alfarsi LH; El Ansari R; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
    BMC Cancer; 2020 May; 20(1):425. PubMed ID: 32410585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy.
    Zhu C; Menyhart O; Győrffy B; He X
    BMC Cancer; 2019 Nov; 19(1):1046. PubMed ID: 31690268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.